Commercialization of a Next-Generation Antibody Development Platform Enabled by Underutilized Shark Resources and Land-Based Rearing Technologies
代表機関名 Ehime University
採択年度 2022
フェーズ Previously Selected
VNAR antibodies, the smallest antibodies derived from sharks, represent a next-generation antibody modality characterized by high engineering flexibility and plasticity, as well as low-cost production.
By utilizing small sharks from underutilized marine resources, we aim to generate high-value VNAR antibodies.
We plan to establish a startup company that provides the “Fukabody Platform”. With support from the SBIR program, we have advanced VNAR development and improved shark rearing technologies. In parallel, we actively conducted commercialization activities, including customer interviews, to refine our business plan and clearly define key milestones toward commercialization.
